Understanding how HIV proteins are expressed in dormant infected cells
Official title: Defining HIV Env protein expression in latently infected cells
Funded at George Washington University · NIH-10899580 · Data updated 2026-11-12
This study is looking at how certain proteins from the HIV virus show up in cells that are hiding the virus, which could help us understand why current antibody treatments aren't fully getting rid of HIV in people on therapy, and it aims to find better treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | August 4, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $201,875 |
| NIH project number | 5R21AI179423-02 |
| Project ID | NIH-10899580 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are on suppressive antiretroviral therapy and may have latent infections.
✕Less likely to help
Patients who are not infected with HIV or those who are not on antiretroviral therapy may not benefit from this research.
What this research studies
This research investigates the expression of HIV Env proteins in cells that are latently infected with the virus. By utilizing advanced assays, the study aims to detect low levels of these proteins, which could help in understanding why current antibody treatments are not effectively clearing the virus in patients on suppressive therapy. The research focuses on the relationship between HIV latency and the potential for using broadly neutralizing antibodies as a therapeutic strategy. Patients may benefit from insights that could lead to improved treatment options for HIV.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for HIV by enhancing the use of broadly neutralizing antibodies.
How similar studies have gone: Previous research has shown promise in using broadly neutralizing antibodies for HIV treatment, but this specific approach to understanding Env protein expression in latent infections is novel.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Lynch, Rebecca Marie — George Washington University
- Study coordinator: Lynch, Rebecca Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.